EMEA-002908-PIP02-22 - paediatric investigation plan

Posoleucel

Key facts

• Active Substance:
  Posoleucel
• Therapeutic area:
  Infectious diseases
• Decision number:
  P/0279/2023
• PIP number:
  EMEA-002908-PIP02-22
• Pharmaceutical form(s):
  Dispersion for infusion
• Condition(s) / indication(s):
  Prevention of viral disease in haematopoietic stem cell transplantation (HCT)
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  AlloVir International DAC; E-mail: [e-mail] ; Tel.: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  14/07/2023

Decision

P/0279/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan for posoleucel (EMEA-002908-PIP02-22)

Reference Number: EMA/283175/2023